Financial Highlights

For the quarter ended Mar’08, the net sales increased by 34% to Rs 63.28 crore. The Operating profit margin grew by 230 bps to 12.8%, which resulted in operating profit to increase by 63% to Rs 8.10 crore. Other income increased by 60% to Rs 1.28 crore which led PBIDT to increase by 62%. The interest cost was up by 156% to Rs 3.16 crore and depreciation also increased by 294% to Rs 2.42 crore. The PBT declined by 3% to Rs 3.80 crore. The company reported tax gain of Rs 1.24 crore compared to tax expense of Rs 0.69 crore in the corresponding previous period. Finally, net profit increased by 56% to Rs 5.04 crore.

• Present order book of the company is Rs 50 crore.
• Till now 23 DMFs are filed, out of which 14 products were launched.
• Company opened an office in Europe for CRAM’s business and Research.
• Cpink Formulation sales for the period FY 2007-08 increased to Rs 18.1 crore compared to Rs 6.5 crore in the corresponding previous period.
• The sales of Rabi plus Formulation is expected to be Rs 24 crore in FY 2008-09.
• Wanbury is the fastest growing domestic Pharmaceutical Company among the top 150 Pharmaceutical companies.
• Company plans to increase the debt by Rs 20 crore in the current year.
• Wanbury started backward integration for some products.
• Key driver for growth is due to increase in the Management Team.
• Wanbury is the world’s largest producer of Metformin with sales of Rs 100 crore.
• Working capital cycle for the API’s will be 90 days and Formulation will be 50 days.
• Capital expenditure for the FY 09 is Rs 20 crore.
• For FY-2009, the Company expects more than 50% topline growth.